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Context. Patients with peripheral neuropathic pain (NP) may only achieve partial pain relief with currently recommended
first-line oral treatments, which are also associated with systemic adverse events. Topical treatments are currently considered
second- or third-line options, but a recent pharmacologic treatment algorithm has called for broader first-line use of these
agents. This has highlighted a need to communicate the benefits associated with topical agents, in particular around the efficacy,
targeted local action, and limited systemic availability resulting in minimal systemic adverse events and drug-drug interactions.
Objectives. This review aims to evaluate the evidence base for topical therapies currently used to treat peripheral NP,
discuss the evidence comparing these treatments head-to-head with oral standard of care, and evaluate how they fit into
treatment regimens in the ‘‘real world.’’
Methods. This is a narrative review.
Results. Two topical treatments are currently licensed: lidocaine 5% medicated plaster (post-herpetic neuralgia) and the
capsaicin 8% patch (peripheral NP). When compared head to head with the oral standard of care (pregabalin), the lidocaine
5% medicated plaster provided similar relief of pain associated with post-herpetic neuralgia but did not meet the primary
predefined criteria for noninferiority. The capsaicin 8% patch, however, demonstrated noninferior efficacy when compared
head-to-head with pregabalin across a wide range of peripheral NP etiologies. Importantly, both treatments demonstrated
effective pain relief without the systemic adverse events associated with oral therapies.
Conclusion. First-line use of topical agents may be of particular benefit in patients where the safety and tolerability of oral
therapy is a concern. J Pain Symptom Manage 2017;53:614e629.  2017 The Authors. Published by Elsevier Inc. on behalf of
American Academy of Hospice and Palliative Medicine. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
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Neuropathic pain (NP) occurs when the nervous sys-
tem itself is diseased or damaged1 and has been defined
as ‘‘occurring as a direct consequence of a lesion or dis-
ease of the somatosensory nervous system.’’2 Peripheral
NP, which includes conditions such as post-traumatic
neuralgia, post-herpetic neuralgia (PHN), painful dia-
betic neuropathy (pDPN), and HIV-related neuropathy3
is extremely challenging to treat.Address correspondence to: Claudia Sommer, MD, Neurologische
Klinik, Universit€atsklinikum W€urzburg, Josef-Schneider-Straße
11, D-97080 W€urzburg, Germany. E-mail: sommer@uni-wuerz
burg.de
 2017 The Authors. Published by Elsevier Inc. on behalf of
American Academy of Hospice and Palliative Medicine. This is an
open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).International guidelines and recommendations
from the European Federation of Neurological Soci-
eties4 and the Special Interest Group on Neuropathic
Pain (NeuPSIG) of the International Association for
the Study of Pain5 recommend oral medicines such
as tricyclic antidepressants, anticonvulsants (including
gabapentin and pregabalin), and selective serotonin
and noradrenalin reuptake inhibitors as first-line op-
tions (Table 1). Despite becoming the mainstay ofAccepted for publication: September 25, 2016.
0885-3924/$ - see front matter
http://dx.doi.org/10.1016/j.jpainsymman.2016.09.015
Table 1
Current Oral and Topical Therapies According to Guideline Recommendations for Use
Treatment Daily dose/regimen
Guideline Recommendations
NeuPSIG5 EFNS4
Anticonvulsants
Pregabalin 150e600 mg/day First-line NP, except trigeminal
neuralgia
300e600 mg/day First-line NP
Gabapentin 1200e3600 mg/day First-line NP First-line NP, except trigeminal
neuralgia
Gabapentin extended
release or enacarbil
1200e3600 mg/day First-line NP
Antidepressants
Tricyclic antidepressants 25e150 mg/day First-line NP First-line NP, except trigeminal
neuralgia; safety concerns in
the elderly
SNRI: Duloxetine 60e120 mg/day First-line NP First-line painful DPN
SNRI: Venlafaxine 150e225 mg/day First-line NP First-line painful DPN
Opioids
Tramadol 200e400 mg/day Second-line NP Second-line NP, except select
conditionsa
Strong opioids Individual titration Third line Second- or third-line NP
Cannabinoids
Cannabinoids Second-line MS and peripheral
NP for refractory cases
Topical
Lidocaine 5% medicated
plasters
3 or fewer per day Second-line peripheral NP;
first line when there are
concerns with side-effects or
safety of first-line treatments,
particularly in frail and
elderly patients
First-line PHN, especially the
elderly if there are concerns
regarding CNS side effects
Capsaicin cream Second-line PHN
Capsaicin 8% patches One to four patches to the
painful area for 30 minutes
(feet) or 60 minutes (other
areas of the body excluding
above the neck) every
three months
Second-line peripheral NP Second-line painful HIV
neuropathies or PHN
Other
Botulinum toxin A 50e200 units, sc, to the painful
area every three months
Third line, specialist use for
peripheral NP
NeuPSIG ¼ Special Interest Group on Neuropathic Pain; EFNS ¼ European Federation of Neurological Societies; NP ¼ neuropathic pain; SNRI ¼ serotonin-
norepinephrine reuptake inhibitor; DPN ¼ diabetic painful neuropathy; MS ¼ multiple sclerosis; PHN ¼ post-herpetic neuralgia; CNS ¼ central nervous system;
HIV ¼ human immunodeficiency virus; sc ¼ subcutaneous.
aTramadol is recommended by the EFNS for second-line use, except for patients with exacerbations of pain (for the tramadol/acetaminophen combination) or
for those with predominant co-existing non-neuropathic pain.
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provide only satisfactory pain relief in 30%e40% of
patients7 and are also associated with undesirable sys-
temic side effects.6,8 Consequently, many individuals
with NP experience persistent pain, poor quality of
life (QoL), and high health care use.9
Topical agents may be preferable to current first-
line systemic therapies; localized activity and low sys-
temic absorption avoids issues associated with oral or
intravenous routes, such as gastric disturbances and
variable serum concentrations, and results in a low
risk of drug-drug interactions.10,13 Two topical treat-
ments are currently licensed by the European Medi-
cines Agency (EMA) for peripheral NP: lidocaine 5%
medicated plaster for PHN only11 and the capsaicin
179 mg (8% w/w) cutaneous patch (capsaicin 8%
patch) for all types of peripheral NP.12 Both thecapsaicin 8% patch and lidocaine 5% patch are
approved for the management of NP associated with
PHN by the Food and Drug Administration.13,14
The NeuPSIG of the International Association for
the Study of Pain has recently updated its recommen-
dations for the pharmacologic management of periph-
eral NP.5 These recommendations take into account
the Grades of Recommendation, Assessment, Develop-
ment and Evaluation (GRADE) system of evaluation,
which look at quality of evidence, effect size, tolera-
bility and safety, and values and preferences
(Table 2). Although the tricyclic antidepressants, gaba-
pentinoids, and serotonin-norepinephrine reuptake
inhibitors remain first-line treatment options, the
topical lidocaine 5% medicated plaster and capsaicin
8% patch are now recommended as second-line ther-
apy for peripheral NP. It is worth noting, however,
Table 2
Summary of GRADE Recommendations for Capsaicin 8% Patch and Lidocaine 5% Medicated Plaster5
GRADE Category Capsaicin 8% Patch Lidocaine 5% Medicated Plaster
Quality of evidence High Low
Balance between desirable and undesirable effects
Effect size Low Unknown
Tolerability and safetya Moderate-high High
Values and preferences High High
Cost and resource allocation Moderate-high Moderate-high
GRADE ¼ Grading of Recommendations Assessment, Development, and Evaluation.
aCommon side effects: lidocaine 5% medicated plaster: local irritation; capsaicin patches: local pain, edema, and erythema.
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evidence has been made available demonstrating non-
inferiority of the capsaicin 8% patch to pregabalin in a
head-to-head trial (A Study to Compare QUTENZA
With Pregabalin for the Treatment of Peripheral
Neuropathic Pain (PNP) After 8 Weeks of Treatment
[ELEVATE]).15 The evidence for topical clonidine
was found to be inconclusive.5
Following a review of current guidelines and the ev-
idence to date, a new pharmacologic treatment algo-
rithm for localized NP has suggested that primary
care physicians and non-pain specialists should
consider first-line use of topical analgesic agents
more broadly.16 Under the proposed model, patients
with a ‘‘good response’’ should continue treatment,
those with a ‘‘partial response’’ should have systemic
therapy added, and those with ‘‘no response’’ should
switch to systemic therapy and/or be referred to a
pain specialist. The authors noted that education
around the efficacy, limited systemic adverse events,
and drug-drug interactions is needed to encourage
widespread adoption of topical treatments in the
first-line setting.
This review aims to address this educational need by
evaluating and discussing the evidence base for topical
therapies in patients with peripheral NP and assessing
how these topical agents fit into clinical practice.
Importantly, this review also highlights and contextu-
alizes findings from direct, head-to-head studies of
topical treatments vs. oral standard of care, including
the ELEVATE trial of the capsaicin 8% patch vs. prega-
balin for the treatment of peripheral NP, which was
recently published.15Evidence for Lidocaine
The lidocaine 5% medicated plaster was first regis-
tered in 1999 in the United States and has been
approved by both the EMA and the U.S. Food and
Drug Administration for the symptomatic relief of
NP associated with previous herpes zoster infection
(i.e., PHN) in adults.11 Its exact mechanism of action
is uncertain, but the primary clinical target is under-
stood to be concerned with interrupting the actionpotential on neurons through voltage-gated sodium
channels, to which it binds in a 1:1 ratio.17 Long-
term pain relief with the lidocaine 5% medicated plas-
ter may be because of both reduced peripheral nerve
input (counteracting central sensitization) and
reduced nerve fiber density in the epidermis.18,19
Each 10  14 cm lidocaine medicated plaster con-
tains 700 mg (5% w/w) of lidocaine in a white hydro-
gel plaster, and a maximum of three patches can be
applied once for up to 12 hours within a 24-hour
period.11 Patients can apply the patch themselves,
although it is recommended that they are re-
evaluated after two to four weeks to ensure analgesic
benefit is achieved. Only around 3% of the lidocaine
is systemically absorbed, but potential risks from sec-
ondary metabolites mean that long-term treatment
with lidocaine 5% medicated plasters is only recom-
mended if there is a therapeutic benefit for the pa-
tient, and caution is advised in those with severe
hepatic or renal impairment.11
Evidence for the Approval of Lidocaine
Positive results for the lidocaine 5% medicated plas-
ter were first seen in a few small placebo-controlled
(vehicle patch) clinical trials, mainly in PHN, showing
this topical medication to be generally effective and
well tolerated (Table 3).20e26 In particular, one ran-
domized, placebo-controlled, two-way, crossover study
in 40 patients with peripheral NP (of various causes)
found the lidocaine 5% medicated plaster to be effec-
tive in relieving ongoing pain (P ¼ 0.017) and allody-
nia (P ¼ 0.023) within the first eight hours after
application, with effects lasting up to one week.25
However, the recent GRADE analysis of the evidence
for the lidocaine 5% medicated plaster by NeuPSIG
found the quality of evidence to be low and only rec-
ommends the treatment as a second-line option in pa-
tients with PHN.5
Head-to-Head Evidence for Lidocaine vs. Oral
Standard of Care
To date, only one study has compared the lidocaine
5% medicated plaster directly with an oral standard of
care.27 In this open-label, multicenter noninferiority
Table 3
Randomized, Double-Blind Studies Providing Evidence for Lidocaine 5% Medicated Plaster Therapy in Patients With Peripheral NP
Study design Patient population
Primary Outcomes
Associated publicationEfficacy Safety
Lidocaine 5% medicated plaster28
Lidocaine 5% medicated plaster vs.
placebo plaster
SC, R, DB, PC, CO study
One plaster applied for 12 hours,
followed by plaster-free interval
of 12 hours. 14-day treatment
period, separated by a 14-day
washout
Severe unilateral inguinal post-
herniorrhapy pain (more than
six months)
n ¼ 21
 Primary end point: percentage
change in summed pain intensity
(six median values, 2 daily
assessments for three days)
 Results: Lidocaine 5% medicated
plaster: 6.6%
Placebo: 0.4%
P ¼ 0.33
Only one AE: mild erythema with
lidocaine and placebo treatment
(resolved after completion)
Bischoff et al. (2013)
Lidocaine 5% medicated plaster vs.
placebo plaster
MC, EE, R, W study
Eight-week, OL phase followed by
two-week, DB, PC phase; up to
three plasters applied for
$12 hours daily
PHN
n ¼ 263 (OL phase)
n ¼ 71 (DB phase)
 Primary end point: Time-to-exit
(two-point reduction or more in
pain relief on two consecutive days
using six-point VAS in DB phase)
 Results: Lidocaine 5% medicated
plaster: 13.5 days (FAS), 14 days
(PP)
Placebo plaster: 9.0 days (FAS), 6 days
(PP)
 P ¼ 0.151 (FAS), P ¼ 0.0398 (PP)
 Most common drug-related AEs
were skin and subcutaneous tissue
disorders; no SAEs considered drug
related
 Total drug-related AEs: 12.8%
OL phase: 16.0%
 DB phase: 4.2%
Binder et al. (2009)b
Lidocaine 5% medicated plaster vs.
placebo plaster
MC, R, DB, PC, two-period, CO
study
Four-week treatment period, up to
three plasters, applied for
#18 hours
Cancer patients with postsurgical
incisional pain for one month or
more
n ¼ 28
 Primary end point: Average weekly
pain intensity rating
 Results: Lidocaine 5% medicated
plaster: 4.1
Placebo: 3.8
P ¼ 0.36
 Reported toxicities were not
significantly different for either
group or time period
Cheville et al. (2009)
Lidocaine 5% medicated plaster vs.
vehicle plaster
MC, R, DB, PC, two-way, CO study
2 seven-day treatment periods, up
to four plasters applied for
$12 hours daily for seven days
Peripheral NP
n ¼ 58 (PHN n ¼ 32)
 Primary end point: Ongoing pain
intensity from two hours to
seven days compared with
pretreatment levels
 Results: Lidocaine: pain intensity
decreased at all time points
(P < 0.001)
Placebo: pain intensity decreased at
all time points (P < 0.05)
 Frequency of events did not differ
between the lidocaine and placebo
groups
Lidocaine phase AEs: n ¼ 20
Placebo phase AEs: n ¼ 17
Meier et al. (2003)
Lidocaine 5% medicated plaster vs.
placebo plaster
Two-center, R, DB, PC, parallel-
group study
PHN
n ¼ 96
 Primary outcome: Efficacy variables
of NPS subitemsa
 Results: Lidocaine 5% medicated
plaster was statistically superior to
 Not reported Galer et al. (2002)b
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Table 3
Continued
Study design Patient population
Primary Outcomes
Associated publicationEfficacy Safety
Treatment duration three weeks vehicle patch in all four composite
analyses:
 NPS 10 (P ¼ 0.043); NPS 8
(P ¼ 0.042), NPS NA (P ¼ 0.022),
and NPS 4 (P ¼ 0.013)
Lidocaine 5% medicated plaster vs.
placebo (vehicle) plaster
Two-center, EE, R, W study.
More than one-month (OL)
lidocaine 5% medicated plaster
followed by 2 two-week DB, PC,
CO with no washout.
Up to three plasters applied for
$12 hours daily for #28 days.
PHN
n ¼ 32
 Primary end point: Time to exit
(two-point reduction or more in
pain relief on two consecutive days
using six-point VAS)
 Results: Lidocaine plaster: >14 days
Placebo (vehicle): 3.8 days
P < 0.001
 No statistical difference between
lidocaine 5% and placebo plasters
with regard to AEs
Galer et al. (1999)b
Lidocaine 5% medicated plaster vs.
placebo (vehicle) plaster
SC, R, DB, PC, CO study
Four sessions: 2 lidocaine 5%
medicated plaster, 1 placebo
patch (and 1 session with
observation only), up to three
plasters applied for $12 hours
daily
PHN
n ¼ 40
 Primary assessment: Pain intensity
(assessed using VAS)
 Results: Mean pain intensity (VAS)
reduced with lidocaine compared
with vehicle (4e12 hours;
P # 0.038) or no treatment (0.5e
12 hours; P # 0.21)
 Patches were well tolerated and
without systemic adverse events
Rowbotham et al. (1996)b
NP ¼ neuropathic pain; SC ¼ single center; R ¼ randomized; DB ¼ double blind; PC ¼ placebo controlled; CO ¼ cross over; AE ¼ adverse event; MC ¼ multicenter; EE ¼ enriched enrollment; W ¼ withdrawal;
OL ¼ open label; PHN ¼ post-herpetic neuralgia; VAS ¼ visual analogue scale; FAS ¼ full analysis set; PP ¼ per protocol; SAE ¼ serious adverse event; NPS ¼ Neuropathic Pain Scale.
aNPS 10: The sum of all 10 NPS descriptors (on a scale of 0e100); NPS 8: a standardized average score defined as the sum of the scores of all 8 descriptor subitems (other than ‘‘intensity’’ and ‘‘unpleasant’’), normalized to
range 0e100; NPS NA: a standardized average score defined as the sum of the scores of all 8 subitems, not intended to include measurement of allodynia/hyperalgesia (i.e. other than ‘‘skin sensitivity’’ and ‘‘surface
pain’’), normalized to range 0e100; NPS 4): a standardized average score defined as the sum of the scores of 4 descriptorsd ‘‘sharp,’’ ‘‘hot,’’ ‘‘dull,’’ and ‘‘deep’’ paindnormalized to range 0e100.
bLidocaine study supporting license approval.
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Fig. 2. Treatment-emergent and drug-related adverse events with lidocaine 5% medicated plaster and pregabalin (SAS).27
AE ¼ adverse event; SAS ¼ safety analysis set.
Fig. 1. Response rate after treatment with lidocaine 5% medicated plaster or pregabalin in patients with PHN and DPN
(PPS).27CI ¼ confidence interval; DPN ¼ painful diabetic polyneuropathy; PHN ¼ post-herpetic neuralgia; PPS ¼ per proto-
col set. ‘‘*’’ Indicates below the predefined margin for noninferiority of 8 percentage points.
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Table 4
Randomized, Double-Blind Studies Providing Evidence for Capsaicin 8% Patch in Patients with Peripheral NP
Study design Patient population
Primary Outcomes
Associated publicationEfficacy Safety
Capsaicin 8% patch studies35,36,38
Capsaicin 8% patch vs. placebo patch
DB, R, PC, MC study
1 30-minute treatment to feet
PDPN (feet)
n ¼ 369
 Primary end point: percentage change
in average daily pain from baseline to
between weeks 2 and 8
Capsaicin 8% patch: 27.4%
Placebo patch: 20.9
 P ¼ 0.025
 TEAEs: Capsaicin 8% patch: 46.8%
Placebo patch: 33.9%
 Majority of TEAEs mild to moderate in
severity
 Three patients with severe drug-related
TEAEs (application site reactions, all in
capsaicin 8% patch group)
Simpson et al. (2017)
Capsaicin 8% patch (30 or 60 minutes)
vs. SOC alone
MC, OL, R, controlled safety study
Repeat treatment (up to 7, $8-week
intervals over 52 weeks) with 30- or
60-minute capsaicin 8% patch
application to feet, or SOC alone
PDPN (feet)
n ¼ 468
 Efficacy end point: mean percentage
change in average pain
Capsaicin 8% patch: 37.5%
(30 minutes); 40.8% (60 minutes)
 SOC alone: 13.9%
 Primary end point: reduction in
Norfolk QoL-DN total score from
baseline to EoS
Capsaicin 8% patch: 27.6 (30 minutes);
32.8% (60 minutes)
SOC alone: 6.7%
 PRAEs: Capsaicin 8% patch: 67.3%
(30 minutes), 69.4% (60 minutes)
 SOC alone: 48.4
Vinik et al. (2015)
Capsaicin 8% patch vs. capsaicin 0.04%
patch
DB, R, controlled study
1  30- or 60-minute application
Painful HIV-AN; n ¼ 494  Primary end point: mean percentage
change in NPRS score from baseline to
weeks 2e12
Capsaicin 8% patch: 29.5% reduction
(30 þ 60 minutes); 30.0% reduction
(60 minutes); 19.1% reduction
(30 minutes)
Capsaicin 0.04% patch: 24.5% reduction
P ¼ 0.097
 Mild-to-moderate transient application
site pain and erythema were the most
common AEs:
Capsaicin 8% patch group: 90% control
group: 62%
 More patients treated with capsaicin
8% patch vs. control had severe
application site events: 19% vs. 2%,
respectively
Clifford et al. (2012)
Capsaicin 8% patch vs. capsaicin 0.04%
patch
MC, DB, R, conformational study
1  60-minute treatment
PHN;
n ¼ 418
 Primary end point: percentage change
in NPRS score from baseline to weeks
2e8
 Results: Capsaicin 8% patch: 32.0%
Capsaicin 0.04% patch: 24.4%
P ¼ 0.011
 TEAEs were mainly application site
specific:
Capsaicin 8% patch: 96%
Capsaicin 0.04% patch 78%
 These AEs were transient and mild-to-
moderate in severity
Irving et al. (2011)
Capsaicin 8% patch vs. capsaicin 0.04%
patch
MC, DB, R, PG, PC study
1 60-minute treatment, 12-week study
duration
PHN;
n ¼ 402
 Primary end point: percentage change
in NPRS score from baseline to weeks
2e8
 Results: Capsaicin 8% patch: 29.6%
Capsaicin 0.04% patch: 19.9%
P ¼ 0.001
 Higher incidence of AEs with capsaicin
8% patch due mainly to local
application-site reactions
Capsaicin 8% patch: 99%
 Capsaicin 0.04% patch: 88%
Backonja et al. (2008)
6
2
0
V
ol.
5
3
N
o.
3
M
arch
2
0
1
7
Som
m
er
an
d
C
ru
ccu
C
ap
sa
ic
in
8%
p
at
ch
(t
re
at
m
en
t)
vs
.
ca
p
sa
ic
in
0.
04
%
p
at
ch
(c
o
n
tr
o
l)
M
C
,
D
B
,
R
,
co
n
tr
o
ll
ed
st
u
d
y
1
30
-,
60
-,
o
r
90
-m
in
u
te
ap
p
li
ca
ti
o
n
P
ai
n
fu
l
H
IV
-A
N
n
¼
30
7
P
ri
m
ar
y
en
d
p
o
in
t:
p
er
ce
n
ta
ge
ch
an
ge
in
N
P
R
S
sc
o
re
(a
ve
ra
ge
p
ai
n
in
la
st
24
h
o
u
rs
)
fr
o
m
b
as
el
in
e
to
w
ee
ks
2e
12
R
es
u
lt
s:
C
ap
sa
ic
in
8%
p
at
ch
gr
o
u
p
:
22
.8
%
C
ap
sa
ic
in
0.
04
%
p
at
ch
:
10
.7
%
re
d
u
ct
io
n
fo
r
co
n
tr
o
ls
P
¼
0.
00
26
S
el
f-
li
m
it
ed
,
m
il
d
-t
o
-m
o
d
er
at
e
lo
ca
l
sk
in
re
ac
ti
o
n
s
co
m
m
o
n
ly
o
b
se
rv
ed
Si
m
p
so
n
et
al
.
(2
00
8)
N
P
¼
n
eu
ro
p
at
h
ic
p
ai
n
;D
B
¼
d
o
u
b
le
b
lin
d
;R
¼
ra
n
d
o
m
iz
ed
;P
C
¼
p
la
ce
b
o
co
n
tr
o
lle
d
;M
C
¼
m
u
lt
ic
en
te
r;
T
E
A
E
¼
tr
ea
tm
en
te
m
er
ge
n
ta
d
ve
rs
e
ev
en
t;
O
L
¼
o
p
en
la
b
el
;N
o
rf
o
lk
Q
o
L
-D
N
¼
N
o
rf
o
lk
Q
u
al
it
y
o
fL
if
ee
D
ia
b
et
ic
N
eu
ro
p
at
h
y;
P
R
A
E
¼
p
o
st
-r
an
d
o
m
iz
at
io
n
ad
ve
rs
e
ev
en
t;
H
IV
-A
N
¼
h
u
m
an
im
m
u
n
o
d
efi
ci
en
cy
vi
ru
s-
as
so
ci
at
ed
n
eu
ro
p
at
h
y;
N
P
R
S
¼
N
u
m
er
ic
P
ai
n
R
at
in
g
Sc
al
e;
A
E
¼
ad
ve
rs
e
ev
en
t;
P
H
N
¼
p
o
st
-h
er
p
et
ic
n
eu
ra
lg
ia
;P
G
¼
p
ar
al
le
lg
ro
u
p
.
Vol. 53 No. 3 March 2017 621Topical Treatments for Peripheral NPtrial, 311 patients with PHN or pDPN were random-
ized 1:1 to either pregabalin (two times daily, titrated
to effect) or 5% medicated plaster. The primary end
point was response rate at four weeks in the per proto-
col set (PPS; n ¼ 281), defined as pain reduction aver-
aged over the last three days from baseline of two
points or more or an absolute value of four points
or less on the Numeric Pain Rating Scale. Noninferior-
ity was not shown for the lidocaine 5% medicated plas-
ter compared with pregabalin for the primary end
point (65.3% vs. 62.0%, respectively; P < 0.007; confi-
dence interval [CI] lower limit of 9.15, which was
below the predefined margin of 8 percentage
points). However, for a group of 88 patients with
PHN (which is the licensed indication), a higher
response was seen in those patients treated with the
lidocaine 5% medicated plaster than with pregabalin
(62.2% vs. 46.5%, respectively) (Fig. 1).
Importantly, patients in the lidocaine 5% medicated
plaster group experienced significantly fewer adverse
events (either treatment emergent or drug related)
compared with the pregabalin group (P < 0.0001)
(Fig. 2). Overall, 16/48 adverse events reported by pa-
tients who received the lidocaine 5% medicated
plaster were drug related, the most common being
headache and application site irritation. In contrast,
161 of 194 adverse events reported by pregabalin
recipients were drug related; these were commonly
related to the nervous system, gastrointestinal tract,
or general disorders, such as fatigue.27Fig. 3. Achievement of a $30% decrease in NPRS score
from baseline to Week 8 (FAS) with capsaicin 8% patch vs.
pregabalin.15 CI ¼ confidence interval; FAS ¼ full analysis
set; NPRS ¼ Numeric Pain Rating Scale.
Table 5
Treatment-Emergent Adverse Events with Capsaicin 8%
Patch Compared with Pregabalin in ELEVATE Study15
TEAE
Capsaicin 8%
patch, n ¼ 282
Pregabalin,
n ¼ 277
Overall n (%) 173 (61.3) 151 (54.5)
Application site pain 67 (23.8) 0 (0.0)
Erythema 59 (20.9) 1 (0.4)
Burning sensation 44 (15.6) 0 (0.0)
Application site erythema 25 (8.9) 0 (0.0)
Pain 15 (5.3) 2 (0.7)
Headache 3 (1.1) 26 (9.4)
Abdominal pain upper 2 (0.7) 8 (2.9)
Nausea 1 (0.4) 30 (10.8)
Asthenia 1 (0.4) 9 (3.2)
Dizziness 0 (0.0) 51 (18.4)
Somnolence 0 (0.0) 43 (15.5)
Weight increased 0 (0.0) 17 (6.1)
Vertigo 0 (0.0) 14 (5.1)
Dry mouth 0 (0.0) 13 (4.7)
Fatigue 0 (0.0) 12 (4.3)
Peripheral edema 0 (0.0) 11 (4.0)
Disturbances in attention 0 (0.0) 8 (2.9)
Diarrhea 0 (0.0) 7 (2.5)
Days free from
drug-related TEAE, %
90.5 70.4
TEAE ¼ treatment-emergent adverse event.
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tant role in the treatment of peripheral NP. Overall,
irrespective of treatment group, two-thirds of patients
with PHN reported their treatment satisfaction to be
‘‘good,’’ ‘‘very good,’’ or ‘‘excellent.’’ Notably, meanFig. 4. Treatment satisfaction scores for medication use at Week
interval; LS ¼ least square; TSQM ¼ Treatment Satisfaction Quchange for the EuroQol five dimensions questionnaire
(EQ-5D) estimated health state score from baseline
and Patient Global Impression of Change Scale
favored the lidocaine 5% medicated plaster indicating
improved health-related QoL with topical medication.
The differences between the patient subpopulations
for efficacy and patient-reported outcomes suggest
that patients with PHN may particularly benefit from
topical treatment. This is reflected by the indication
of the lidocaine 5% medicated plaster for the symp-
tomatic relief of NP associated with PHN in adults.11,12Other Evidence for Lidocaine
The paucity of double-blind randomized clinical tri-
als evaluating lidocaine for the treatment of periph-
eral NP has been highlighted in a recent Cochrane
review, which identified 12 studies (n ¼ 508) all
comparing topical lidocaine with placebo.28 The re-
view identified that various formulations had been
used (i.e., 5% medicated plaster, gel and cream and
an 8% spray) in studies of differing designs, each
involving relatively few participants with various neuro-
pathic conditions outside the current license. The
studies were mainly of short duration (i.e., up to
12 weeks) and it was not possible to determine
whether the early response to topical lidocaine is
maintained long term. The authors, therefore,
concluded that the available studies support the use8 with capsaicin 8% patch vs. pregabalin.15 CI ¼ confidence
estionnaire for Medication.
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with PHN and noted that that this topical treatment is
well tolerated in the short term.28Evidence for Capsaicin
The capsaicin 8% patch was first approved for
nondiabetic patients with peripheral NP but has subse-
quently received EU approval for a label extension to
include all patients with peripheral NP, either alone or
in combination with other medicinal products for
pain.12 Capsaicin is the active component in fruits of
the genus Capsicum and an agonist of the transient re-
ceptor potential vanilloid-I receptor (TRPVI).29 It
causes an initial enhanced sensitivity of TRPV1-
expressing cutaneous nociceptors, followed by persis-
tent desensitization leading to a durable analgesic
effect.30 Morphologically, capsaicin causes a signifi-
cant reduction in epidermal nerve fiber density, recov-
ering after 24 weeks in healthy volunteers.30
Each 14  20 cm patch is designed to deliver a sin-
gle therapeutic dose of capsaicin over 30 minutes
(feet) or 60 minutes (other locations), after which
time the patch is removed. The treatment area should
be determined and marked by a physician, and only a
physician (or healthcare professional under the super-
vision of a physician) should apply the capsaicin 8%
patch. A maximum of four patches can be applied in
a single treatment, which may be repeated every
90 days if required.12Evidence for the Approval of Capsaicin 8% Patch
The approval of the capsaicin 8% patch was based
on randomized, double-blind, placebo-controlled
studies in patients with PHN,31,32 painful HIV neurop-
athy,33,34 and pDPN,35e37 which have demonstrated
rapid and sustained pain relief after a single
treatment,31e35 and long-term safety and efficacy of
repeat treatments over 52 weeks.36,37 The most recent
of these studies A Study to Evaluate Efficacy and Safety
of a Single Application of Capsaicin 8%Transdermal
Delivery System Compared to Placebo in Reducing
Pain Intensity in Subjects With Painful Diabetic Pe-
ripheral Neuropathy (PDPN) (STEP)35 was the first
assessment of the efficacy and safety of the capsaicin
8% patch vs. placebo in patients with pDPN. Patients
treated with the capsaicin 8% patch showed statisti-
cally significant improvements in pain relief
(P ¼ 0.025) and sleep quality (P ¼ 0.030) compared
with placebo, and treatment was well tolerated with
no associated sensory deterioration or new safety con-
cerns (Table 4).
The recent NeuPSIG GRADE analysis found the qual-
ity of evidence for the capsaicin 8% patch to be high(Table 2), and currently recommends the capsaicin
8% patch as second-line treatment of peripheral NP.5
Head-to-Head Evidence for Capsaicin 8% Patch Vs.
Oral Standard of Care
The recent head-to-head, open-label, randomized
(1:1), multicenter, noninferiority study (ELEVATE) is
the only randomized controlled trial to directly
compare the capsaicin 8% patch with a first-line oral
treatment.15 This study assessed the efficacy and toler-
ability of the capsaicin 8% patch with pregabalin in
559 nondiabetic adult patients with various etiologies
of peripheral NP.15 Importantly, patients had to be
either naive to treatment with the capsaicin 8% patch
and either naive to treatment with pregabalin and ga-
bapentin, or, in the opinion of the investigator, had
not received adequate treatment with pregabalin or
gabapentin. The primary outcome of efficacy was
$30% pain relief from baseline to Week 8, and the pri-
mary analysis was performed in the full analysis set
(FAS) and PPS. The capsaicin 8% patch was shown
to provide noninferior pain relief to an optimized
dose of pregabalin; the primary outcome was achieved
by 55.7% of patients in the capsaicin 8% patch group
and by 54.5% in the pregabalin group (FAS). The dif-
ference (capsaicin 8% patchepregabalin) in the pro-
portion of responders was 1.2% for the FAS analysis,
with an odds ratio 1.03 (95% CI 0.71, 1.50), which
was above the predefined margin for noninferiority
of 0.693 (Fig. 3); analysis of the PPS population also
found the capsaicin 8% patch to be noninferior to
pregabalin (odds ratio 1.03, 95% CI 0.70, 1.52). In
addition, time to onset of pain relief was found to
be significantly shorter with capsaicin 8% patch vs.
pregabalin (7.5 vs. 36.0 days, respectively; P < 0.0001).
To reflect current clinical practice and to try to mini-
mize the occurrence of treatment-emergent adverse
events (TEAEs) as much as possible, the study included
an up- and down-titration scheme for pregabalin, per-
formed over a period of four weeks, with the optimal
dose maintained from weeks 4 to 8. Although the num-
ber of TEAEs was higher with the topical capsaicin 8%
patch, compared with pregabalin, it was associated
with fewer systemic side effects (Table 5). TEAEs with
the topical patch were largely application-related site re-
actions, which were generally mild-to-moderate and did
not lead to study drug discontinuation in any patient. In
contrast, 24 patients (8.5%) withdrew from the pregaba-
lin group due to TEAEs. Three serious adverse events
were reported in the study: one with the capsaicin patch
(burn at application site) and two with pregabalin (car-
diac failure and swollen tongue). Overall, a greater pro-
portion of patients withdrew from the study because of
either a lack of efficacy or insufficient tolerability with
pregabalin (9.7%), compared with the capsaicin 8%
patch (0.7%), and more capsaicin-treated patients
624 Vol. 53 No. 3 March 2017Sommer and Cruccuwere willing to continue treatment by study end
compared with those treated with pregabalin (78.4 vs.
66.4%, respectively). Furthermore, the ELEVATE study
highlighted significant differences in patient perception
of effectiveness, side effects, and global satisfaction
(Fig. 4), all favoring the capsaicin 8% patch.15Other Evidence for Capsaicin 8% Patch
The study findings that led to the approval of the
capsaicin 8% patch are supported by a Cochrane re-
view of six randomized, double-blind, placebo-
controlled studies involving 2073 patients: four studies
of PHN and two of painful HIV neuropathy.38 More
patients achieved high levels of controlled pain relief
with the capsaicin 8% patch vs. control (0.04% capsa-
icin for blinding), and patients with high levels of pain
relief also reported additional improvements in sleep,
fatigue, depression, and an improved QoL. Serious
adverse effects were no different between the two
groups38; however, a lack of long-term safety data after
repeated applications was noted at the time.
Safety and Effectiveness of Repeated Administration
of QUTENZA Patches for Treatment of Pain Caused
by Nerve Damage (STRIDE) was the first prospective
study to assess the long-term safety, tolerability, and
analgesic effectiveness of capsaicin 8% patch repeat
treatment (up to six retreatments) over 52 weeks, in
306 patients with a broad range of peripheral NP etiol-
ogies.39,40 Repeated treatment with the capsaicin 8%
patch was well tolerated and did not result in a detri-
mental change in sensation or raise any new safety
concerns.40 Although a large proportion of patients
discontinued the study (130 patients, 42.5%), only
1% of cases were due to drug-related TEAEs.40
Furthermore, the capsaicin 8% patch was associated
with a substantial and sustained reduction of pain;
the overall change in average daily pain intensity was
2.1 (SD 1.7; 95% CI 2.46 to 1.78) from baseline
to Month 12 for 100 patients who received four
consecutive capsaicin 8% patch applications. Patient
Global Impression of Change also improved with
capsaicin 8% patch treatment: just more than 31%
of patients reported themselves to be ‘‘very much
improved’’ or ‘‘much improved’’ at the end of this
long-term study.39Evidence for Other Topical Therapies
Topical administration of locally acting agents,
including cannabinoids, has been reported on a
case-study basis, but no evidence from randomized
controlled trials is available to discuss. Botox injec-
tions have some evidence base for pain relief sup-
ported by a few small clinical trials but fall outsidethe scope for this review because of the subdermal,
injection-based application process.
Investigational data for topical clonidine, amitripty-
line, and ketamine are available for discussion.
Topical Clonidine
Topical clonidine, an a-adrenergic receptor agonist,
is currently under investigation for the treatment of pe-
ripheral NP because of its locally mediated effect that
may reduce hypersensitivity after nerve injury.41,42 Its
potential to provide pain relief in somepatients was first
shown in two early small trials in sympathetically main-
tained pain (six patients)43 and pDPN (41 patients).44
The pDPN study was a two-stage, double-blind, random-
ized, enrichment study; although no significant differ-
ence between topical clonidine and placebo was
observed in the first one-week treatment period, a sig-
nificant difference was achieved in the second phase.
This involved only 12 responders from the first phase
who reported 20% reduction in pain with clonidine
than placebo (P¼ 0.015).44 A post hoc analysis of these
data suggested that patients who describe their pain as
being sharp and shooting have a greater likelihood of
responding to clonidine. In a small pilot open-label
study of 17 patients with orofacial pain, only partial
pain reduction with topical clonidine was reported in
five of 10 patients with ‘‘neuropathic pain’’ other than
trigeminal neuralgia; however,more promising pain re-
lief was reported in four of seven patients with ‘‘neural-
gia-like’’ pain,45 which would confirm the previous
study finding that clonidine may be more effective in
paroxysmal pain.
Although findings from these initial observations
were varied, they provided the rationale for exploring
topical clonidine in a randomized (1:1) double-blind,
placebo-controlled clinical trial of 179 patients with
pDPN.46 Topical clonidine was found to be well toler-
ated, with no serious adverse events reported and was
more effective compared with placebo (P < 0.05) for
those patients who felt pain when exposed to capsa-
icin (used as a test of nociceptor function). Therefore,
patients with pDPN who have functional nociceptors
may potentially benefit from this type of topical treat-
ment, but its use in this population is currently unli-
censed and further clinical trials are warranted.
Amitriptyline and Ketamine
Amitriptyline is an antidepressant with notable ac-
tion across a wide range of ion channels and
receptors.47e49 Although the extensive number of
target sites has led to limited use of amitriptyline as
an oral therapy due to adverse events, local adminis-
tration of amitriptyline has been investigated as a po-
tential candidate for the treatment of peripheral NP.
These studies include several topical formulations of
varying doses and investigate its use both as
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mine, an anesthetic agent usually administered orally
or via subcutaneous infusion.
One double-blind, placebo-controlled crossover
study randomized 35 patients with postsurgical NP
(n ¼ 13), PHN (n ¼ 8), or diabetic painful neuropathy
(n ¼ 14) to apply 5% amitriptyline, 5% lidocaine, or
placebo twice daily for one week. No statistical signifi-
cance for either amitriptyline or lidocaine was reached
compared with placebo, although the authors noted
that lack of efficacy might have been because of low
baseline pain scores.50
A pilot double-blind study evaluating the topical
combination of 1% amitriptyline and 0.5% ketamine
failed to show a treatment effect after a treatment
period of two days. However, an open-label extension
of up to one week in 11 patients did demonstrate sig-
nificant pain relief from days 3 to 7 with the combina-
tion cream vs. placebo.51 A larger double-blind study
in 92 patients with diabetic neuropathy (n ¼ 20),
PHN (n ¼ 14), and postsurgical/post-traumatic pain
(n ¼ 58) randomized patients to one of four creams
(placebo, 2% amitriptyline, 1% ketamine, or 2%
amitriptylinee1% ketamine combined) three times
daily for three weeks. No significant effect was found
for any treatment compared with placebo at the pri-
mary end point (Week 3)52; however, a six-month,
open-label extension of the study completed by 21 pa-
tients (diabetic neuropathy [n ¼ 3]; PHN [n ¼ 2];
postsurgical/post-traumatic pain [n ¼ 16]) found
that by Month 6, patients reported an average of
34% reduction in pain, with five patients reporting
50% reduction or more in pain and one achieving
100% reduction in pain.53
Importantly, in all these studies, blood assessments
revealed minimal systemic absorption and few adverse
events were reported. Taken together, these studies
show the potential benefit of topical amitriptyline
and ketamine in providing pain relief, but further ran-
domized trials are needed to establish the appropriate
dose and length of treatment to fully understand the
role of this combination in treating peripheral NP.Observational, Noninterventional, and
Retrospective Evidence for Topical Treatments
When considering the different therapeutic
approaches, it is important to take account of data
from observational, noninterventional, and retrospec-
tive studies. These data often have the advantage of
high patient numbers and can be used post-approval
to help to identify patient types that most benefit
from treatment. These data can also provide an oppor-
tunity to investigate how treatments are being inte-
grated within clinical practice. Few data of topicalpatch use in patients with peripheral NP outside ran-
domized, controlled trials have been published, but
those that are available provide further support to
the evidence base.54e56
Observational Evidence for Lidocaine 5% Medicated
Plaster
Only one large, retrospective, observational study
has investigated the efficacy and safety of the lidocaine
5% medicated plaster in a cohort of French patients
(n ¼ 467) who had been treated in pain centers
between 2001 and 2006 with various types of peripheral
NP. Overall, 20.6% of the patients had PHN (the cur-
rent indication) and more than three-quarters
(76.3%) had other types of peripheral NP including
post-surgery pain, post-traumatic pain, and cancer-
related pain.54 In the overall population, the mean
duration of treatment was less than three months in
42% of patients, three to 12 months in 37%, and
more than a year in 21%of patients. Treatment resulted
in a >50% reduction in pain intensity in 46% of pa-
tients and a reduction of at least 30% in 82% of
patients.54
Noninterventional Evidence for Capsaicin 8% Patch
One of the largest noninterventional studies of
topical medical patches was the three-month QUEPP
(Qutenzadsafety and effectiveness in peripheral NP)
study.56,57 This was conducted in Germany between
March 2011 and 2012 and evaluated the safety and
effectiveness of a single application of the capsaicin
8% patch in 1044 nondiabetic patients with peripheral
NP. Approximately 41% of patients had at least 30%
pain relief, whereas a further 24% experienced at least
50% pain relief, during the follow-up period (between
weeks 1 or 2 and Week 12 after treatment) in this real-
world setting. Over the three-month period, the levels
of pain intensity also declined by around 25% in these
patients. Significant improvements in pain attacks,
sleep parameters, daytime tiredness, and the addi-
tional intake of analgesic drugs were also reported
(all P # 0.001).55 Of interest, patients with a history
of pre-existing peripheral NP of less than six months
had the highest treatment response to the capsaicin
8% patch; 30% and 50% responder rates in these pa-
tients were around 62% and 39%, respectively,
compared with 42% and 23% in patients experiencing
pain for six months to two years; 41% and 22% in
those with pain for more than two to 10 years; and
32% and 14% in those with pain for >10 years.57
These findings suggest that early initiation of topical
capsaicin 8% patch treatment is of particular benefit
to patients.
The prospective, noninterventional ASCEND study
was performed to characterize the retreatment inter-
val, patch use, and clinical effectiveness of the
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seven European countries. Interim results for 340 pa-
tients are available58; eight weeks after first capsaicin
8% patch treatment, 42.7% of patients achieved a
30% reduction in mean Numeric Pain Rating Scale
score, and 24.8% achieved a 50% reduction. The me-
dian time from first to second treatment was 22 weeks
and from second to third was a further 20 weeks, and
the mean number of patches used at the first, second,
and third applications was 1.4 (0.74), 1.5 (0.65), and
1.6 (0.94), respectively. Taken together, these results
suggest that capsaicin 8% patch use and retreatment
intervals are stable across successive treatments and
indicate consistent efficacy.57Patient Selection and Place of Topical Treatments
in Clinical Practice
From a clinical perspective, it is always helpful to be
able to predict which patients will most benefit from
particular types of pain management strategies. At-
tempts to predict which patients are most likely to
respond to topical lidocaine have generally been un-
successful,59,60 only showing trends in small patient
populations,61 or in patient populations outside the
current license (PHN). Based on a retrospective re-
view of data from 41 patients, pain specialists from
17 countries identified localized pain, hyperalgesia,
and/or allodynia and other positive sensory symptoms
(such as dysesthesia) as having a positive predictive
value for the efficacy of lidocaine 5% medicated plas-
ter in patients with chronic back pain with neuro-
pathic components.62 In contrast, widespread pain
and negative sensory symptoms were identified as be-
ing negative predictors for efficacy.62 Patients who
are lidocaine naive may benefit from topical lidocaine
5% medicated plaster treatment,27 and both Euro-
pean Federation of Neurological Societies and Neu-
PSIG recommend that this topical patch be used
first line when there are concerns about side effects
or the tolerability of systemic oral treatments, particu-
larly in frail or elderly patients.5,63 However, caution is
advised in certain patient populations, in particular
patients with severe hepatic or renal impairment.11
Effective lidocaine pretreatment and high pre-
treatment pain score variability have been identified
as positive predictors of treatment response to the
capsaicin 8% patch.64 Based on data from 1248 patients
across four double-blind, randomized controlled
studies of the capsaicin 8% patch compared with an
active control, patients are more likely to respond if
they do not have a rigid and fully manifested chronic
pain process with severe central plastic changes.64 A
further meta-analysis of six randomized controlled
studies found that a baseline pain intensity score of 4or less was a predictor of sustained and complete
response in patients with PHN and HIV neuropathy.65
Other characteristics associated with response to capsa-
icin 8% patch were absence of allodynia, presence of
hypoesthesia, and McGill Pain Questionnaire sensory
score <22 (patients with PHN) and the female sex (pa-
tients with HIV neuropathy).65
As capsaicin acts on the vanilloid receptors, patients
with preserved warmth sensitivity and continuous
burning pain are likely to be the best responders to
the capsaicin 8% patch. In addition, patients experi-
encing pain for less than six months may benefit
most from topical capsaicin 8% patch treatment, as
shown in the QUEPP study.58 Given these findings,
the capsaicin 8% patch may be a good option where
renal and hepatic impairment is of concern as there
is no restriction for its use in these patient groups.12Practical Considerations
Although efficacy, safety, and tolerability are the pri-
mary considerations when selecting the optimal pain
therapy, it is also of value to understand the practical
elements of different topical treatments. The capsaicin
8% patch must be applied by a physician (or a health
care professional under the supervision of a physician),
for 30 minutes (to the feet) or 60 minutes (to other
areas of the body), with retreatment every 90 days as
required. In contrast, the lidocaine 5% medicated plas-
ter can be applied by patients themselves for up to
12 hours within a 24-hour period, but patients require
evaluation at two to four weeks after treatment initia-
tion. Considering these differences, clinicians will
need to factor patient preference, monitoring require-
ments, duration of treatment administration, duration
of analgesic benefits, and any potential for nonadher-
ence between patient- and physician-administered
topical treatments, alongside the efficacy and safety
data when choosing between these topical agents.Conclusions and Recommendations for Future
Research
Topical agents that have an effect on the peripheral
nervous system are effective at delivering rapid, tar-
geted pain relief of peripheral NP without the side ef-
fects associated with systemic, oral therapies.15,27 Two
topical agents are currently licensed by the EMA, the
lidocaine 5% medicated plaster specifically for pa-
tients with PHN11 and the capsaicin 8% patch for
adults with peripheral NP.12 The Food and Drug
Administration has approved both agents for the man-
agement of NP associated with PHN13,14 Given their
proved efficacy, local action, and favorable safety
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useful in various patient groups, such as those where
there are concerns about systemic side effects, compli-
ance, and in patients who are frail or elderly.5,63
Predicting the patient profile that would gain the
most benefit from early treatment would be advanta-
geous, thereby avoiding ‘‘trial and error’’ management
scenarios that often arise.66 Evidence from the clinical,
observational, and noninterventional studies for capsa-
icin 8% patch supports early treatment use with short
duration of pain having a positive predictive value on
the efficacy of this topical treatment.55,64 Initial
screening with a local anesthetic (e.g., lidocaine) could
also help to identify those patients who would respond
best to the capsaicin 8% patch.64 Evidence of predictors
of efficacy with the lidocaine 5% medicated plaster is
not as strong as for the capsaicin 8% patch, but it has
been proposed by several pain specialists that they are
effective for localized pain, hyperalgesia, and/or allody-
nia and where there is a positive sensory input.62 This
treatment may also benefit patients who are treatment
naive and those who are refractory to oral treatment.5,54
Further studies designed to evaluate factors that might
predispose to a successful outcome with these topical ap-
proaches are awaited to help guide treatment.3
At present, one study has compared the lidocaine
5% medicated plaster directly with a first-line oral
agent and one study has compared the capsaicin 8%
patch directly with a first-line oral agent.15,27 Noninfer-
iority was not shown for the lidocaine 5% medicated
plaster when investigated head-to-head with pregaba-
lin,27 but the ELEVATE trial successfully showed that
capsaicin 8% patch was noninferior to pregabalin in
relieving pain when compared head-to-head across a
wide variety of peripheral NP etiologies.15 Despite
this recent evidence, there is an urgent need for
more high-quality head-to-head, randomized,
controlled studies for topical treatments to enable
direct comparisons of treatment outcomes with cur-
rent first-line oral therapies.67,68 These studies should
be of sufficient duration and include specific patient
subtypes at risk of refractory peripheral NP.68Disclosures and Acknowledgments
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